CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Hemotune is developing a blood purification device using magnetic nanoparticles to treat sepsis, a life-threatening condition caused by endotoxins. This innovative technology aims to remove harmful molecules from the bloodstream, potentially stabilizing patients and addressing a significant unmet medical need.
Hemotune is a Swiss academic spin-off company founded in 2017 to commercialize proprietary blood purification technology using uniquely designed magnetic nanoparticles, developed at ETH Zürich.
Hemotune is financially supported by Wyss Zurich and the Gebert Rüf foundation to develop a product to treat sepsis.
Sepsis affects 19 million people each year, and with a mortality rate of 30% it is the most common cause of death in intensive care units.
Currently, no cure for sepsis exists, and treatmen…
HEMOTUNE AG
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
